CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Li Tzong Chen; Andrea Wang-Gillam; Yan Shen Shan; Teresa Macarulla; Jean Frédéric Blanc; Richard Hubner; Chang Fang Chiu; Gilberto Schwartsmann; Jens Siveke; Pipas J. Marc; Bruce Belanger; Floris de Jong; Khalid Mamlouk; Daniel Von Hoff

doi:10.1093/annonc/mdx263.016

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Li Tzong Chen, Andrea Wang-Gillam, Yan Shen Shan, Teresa Macarulla, Jean Frédéric Blanc, Richard Hubner, Chang Fang Chiu, Gilberto Schwartsmann, Jens Siveke, Pipas J. Marc, Bruce Belanger, Floris de Jong, Khalid Mamlouk, Daniel Von Hoff

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	iii6-iii7
Journal	Annals of Oncology
Volume	28
DOIs	https://doi.org/10.1093/annonc/mdx263.016
State	Published - Jun 2017

Access to Document

10.1093/annonc/mdx263.016

Cite this

Chen, L. T., Wang-Gillam, A., Shan, Y. S., Macarulla, T., Blanc, J. F., Hubner, R., Chiu, C. F., Schwartsmann, G., Siveke, J., Marc, P. J., Belanger, B., de Jong, F., Mamlouk, K., & Von Hoff, D. (2017). CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of Oncology, 28, iii6-iii7. https://doi.org/10.1093/annonc/mdx263.016

@article{058d7f2a22614ee8a664c2d6773da3bd,

title = "CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy",

author = "Chen, {Li Tzong} and Andrea Wang-Gillam and Shan, {Yan Shen} and Teresa Macarulla and Blanc, {Jean Fr{\'e}d{\'e}ric} and Richard Hubner and Chiu, {Chang Fang} and Gilberto Schwartsmann and Jens Siveke and Marc, {Pipas J.} and Bruce Belanger and {de Jong}, Floris and Khalid Mamlouk and {Von Hoff}, Daniel",

year = "2017",

month = jun,

doi = "10.1093/annonc/mdx263.016",

language = "English",

volume = "28",

pages = "iii6--iii7",

journal = "Annals of Oncology",

issn = "0923-7534",

}

Chen, LT, Wang-Gillam, A, Shan, YS, Macarulla, T, Blanc, JF, Hubner, R, Chiu, CF, Schwartsmann, G, Siveke, J, Marc, PJ, Belanger, B, de Jong, F, Mamlouk, K & Von Hoff, D 2017, 'CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy', Annals of Oncology, vol. 28, pp. iii6-iii7. https://doi.org/10.1093/annonc/mdx263.016

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. / Chen, Li Tzong; Wang-Gillam, Andrea; Shan, Yan Shen et al.
In: Annals of Oncology, Vol. 28, 06.2017, p. iii6-iii7.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

AU - Chen, Li Tzong

AU - Wang-Gillam, Andrea

AU - Shan, Yan Shen

AU - Macarulla, Teresa

AU - Blanc, Jean Frédéric

AU - Hubner, Richard

AU - Chiu, Chang Fang

AU - Schwartsmann, Gilberto

AU - Siveke, Jens

AU - Marc, Pipas J.

AU - Belanger, Bruce

AU - de Jong, Floris

AU - Mamlouk, Khalid

AU - Von Hoff, Daniel

PY - 2017/6

Y1 - 2017/6

UR - http://www.scopus.com/inward/record.url?scp=85079680827&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx263.016

DO - 10.1093/annonc/mdx263.016

M3 - Article

C2 - 32135959

SN - 0923-7534

VL - 28

SP - iii6-iii7

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Chen LT, Wang-Gillam A, Shan YS, Macarulla T, Blanc JF, Hubner R et al. CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of Oncology. 2017 Jun;28:iii6-iii7. doi: 10.1093/annonc/mdx263.016

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Access to Document

Other files and links

Cite this